Trxade Group (NASDAQ: MEDS), an integrated drug
procurement, delivery and healthcare platform that enables price transparency
and increased profit margins to healthcare buyers and sellers of
pharmaceuticals, on Tuesday announced the closing of its underwritten public
offering of 806,452 shares of common stock at a price to the public of $6.50
each. The company granted the underwriters a 45-day option to obtain up to an
additional 120,967 shares of common stock to cover any overallotments. Before
the deduction of underwriting discounts and offering expenses, the company
secured gross proceeds of $5.24 million from the offering, which it plans to
utilize toward working capital, general corporate purposes and potentially to
fund acquisitions of other companies, products or technologies. ViewTrade
Securities, Inc. acted as an underwriter of the offering, while Dawson James
Securities, Inc. and Dougherty & Company LLC acted as both underwriters and
co-book running managers.
To view the full press release, visit http://ibn.fm/mJ0cb
About Trxade Group, Inc.
Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ:
MEDS) is an integrated drug procurement, delivery and healthcare platform that
enables price transparency and increased profit margins to healthcare buyers
and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of
three synergistic operating platforms; the Trxade B2B trading platform with
11,900 registered pharmacies, licensed virtual Wholesale and Mail Order
Pharmacy delivery capabilities using DelivMeds app. For additional information,
visit the company’s website at www.Trxade.com.
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
